A minority of patients with functional seizures have abnormalities on neuroimaging

Wesley T. Kerr a,b,⁎, John K. Lee a, Amir H. Karimi a, Hiroyuki Tatekawa c, L. Brian Hickman a,d, Michael Connerney b, Siddhika S. Sreenivasan a, Ishita Dubey a, Corinne H. Allas a, Jena M. Smith a, Ivanka Savic a,c, Daniel H.S. Silverman f, Lubomir M. Hadjiiski g, Nicholas J. Beimer b,l, William C. Stacey h, Mark S. Cohen a,b,c,k, Jerome Engel Jr a,b,l,m, Jamie D. Feusner b,e,n,o,p, Noriko Salamon a,c, John M. Stern a

a Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
b Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA
c Department of Radiation and Biomedical Science, University of California Los Angeles, Los Angeles, CA, USA
d Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
e Department of Internal Medicine, University of California at Irvine, Irvine, CA, USA
f Department of Women’s and Children’s Health, Karolinska Institute and Neurology Clinic, Karolinska University Hospital, Karolinska Universitetssjukhuset, Stockholm, Sweden
h Department of Neurology, University of Toronto, Toronto, Canada
i Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
j Departments of Bioengineering, Psychology and Biomedical Physics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
k Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

ARTICLE INFO

Keywords:
Decision analysis
Clinical diagnostics
Psychogenic non-epileptic seizures
Conversion disorder
Dissociative seizures

ABSTRACT

Objective: Functional seizures often are managed incorrectly as a diagnosis of exclusion. However, a significant minority of patients with functional seizures may have abnormalities on neuroimaging that typically are associated with epilepsy, leading to diagnostic confusion. We evaluated the rate of epilepsy-associated findings on MRI, FDG-PET, and CT in patients with functional seizures.

Methods: We studied radiologists’ reports from neuroimages at our comprehensive epilepsy center from a consecutive series of patients diagnosed with functional seizures without comorbid epilepsy from 2006 to 2019. We summarized the MRI, FDG-PET, and CT results as follows: within normal limits, incidental findings, unrelated findings, non-specific abnormalities, postsurgical study, epilepsy risk factors (ERF), borderline epilepsy-associated findings (EAF), and definitive EAF.

Results: Of the 256 MRIs, 23% demonstrated ERF (5%), borderline EAF (8%), or definitive EAF (10%). The most common EAF was hippocampal sclerosis, with the majority of borderline EAF comprising hippocampal atrophy without T2 hyperintensity or vice versa. Of the 87 FDG-PETs, 26% demonstrated borderline EAF (17%) or definitive EAF (8%). Epilepsy-associated findings primarily included focal hypometabolism, especially of the temporal lobes, with borderline findings including subtle or questionable hypometabolism. Of the 51 CTs, only 2% had definitive EAF.

Abbreviations: ASM, antiseizure medication; ES, Epileptic Seizures; FS, Functional Seizures; MRI, Magnetic Resonance Imaging; PET, fluorodeoxyglucose-potisiton emission tomography; CT, X-ray computed tomography; SPECT, single positron emission spectroscopy; EEG, electroencephalography; vEEG, video-electroencephalography; ERF, Epilepsy risk factors; EAF, Epilepsy-associated findings; UCLA, University of California, Los Angeles; T, Tesla.

E-mail address: WesleyTK@g.UCLA.edu (W.T. Kerr).

https://doi.org/10.1016/j.jns.2021.117548
Received 28 May 2021; Received in revised form 12 June 2021; Accepted 16 June 2021
Available online 18 June 2021
0022-510X/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction

Functional seizures (FS) are paroxysmal events where patients lose conscious control of their movements, awareness, or sensations [1]. Alternate terms for FS include dissociative seizures and psychogenic nonepileptic seizures [2–4]. While these seizures may appear behaviorally similar to epileptic seizures (ES), they are not caused by abnormal epileptic neural activity and are not treated with antiepileptic medications (ASMs) [5,6]. Instead, the term, functional seizures, represents an abnormality of the function of the nervous system that is not typically associated with a definitive structural abnormality [2].

Consequently, clinicians may presume that neuroimaging of patients with FS would be normal, and abnormal neuroimaging should cast doubt on the diagnosis. However, multiple retrospective studies have demonstrated radiologically apparent abnormalities in 30% of magnetic resonance images (MRIs) from patients with FS without comorbid ES [7–14]. While the majority of these abnormalities were nonspecific, two previous studies found that 5–10% of them had definitive epilepsy-associated findings (EAF) including hippocampal sclerosis [7,10]. This rate of nonspecific abnormalities is markedly higher than healthy controls, who typically have nonspecific findings on 2–18% of MRIs, with the rate of EAF being too low to quantify reliably [15–24]. In the years following most of these prior studies, the development of epilepsy-specific scanning protocols and widespread adoption of 3 Tesla scanners have led to higher image quality and sensitivity for subtle abnormalities [8,25]. In patients with temporal lobe epilepsy with hippocampal sclerosis, 86% of 1.5 Tesla MRIs using standard protocols failed to illustrate this key finding [26,27]. Therefore, the rate of neuroimaging abnormalities in FS should be re-addressed.

In addition to these findings that were detectable using visual analysis by a specialized neuroradiologist, quantitative neuroimaging has demonstrated significant morphometric, connectivity and metabolic changes in patients with FS as compared to seizure-naive controls and patients with epilepsy [28–39]. Quantitative morphometry has demonstrated changes in the left amygdala, right hippocampus, left insula, left lateral orbital cortex, and bilateral medial orbital cortices [30,40]. In addition to these morphometric changes, there are alterations in the connectivity of the limbic network, executive control network, and motor control networks in multiple areas as measured using functional MRI, diffusion tractography, single positron emission spectroscopy (SPECT), and high-density electroencephalography (EEG) [41–44]. Each of these findings suggest that there are observable changes in the structure of the brain in functional seizures, in addition to changes in the function.

We hypothesized that the rate of radiologically apparent findings in patients with FS was related to the use of higher quality imaging protocols. As nonspecific or equivocal findings are a common challenge in clinical practice, we also hypothesized that the frequency of borderline ERF or EAF may be associated less strongly with epilepsy (e.g. prior intracerebral hemorrhage). Because our protocol includes the acquisition of interictal florodeoxyglucose-positron emission tomography (PET) on the first day of video-EEG (VEEG) monitoring, we uniquely evaluate the hypothesis that the frequency of ERF and EAF on PET may be similar to MRI, and they may correlate within the same patient. Lastly, we hypothesized that ERF or EAF may be associated with key clinical factors and these associations may provide further interpretation on the impact or consequence of abnormal imaging on clinical care.

2. Material and methods

Our patient population includes all patients with functional seizures admitted to the UCLA adult vEEG monitoring unit between January 2006 and December 2019. Diagnosis met the International League Against Epilepsy criteria for “documented” [1], and was formed using expert clinical opinion based on the available clinical history, physical exam, ictal vEEG, and structural MRI. We excluded patients with mixed functional and epileptic seizures, because EAF on neuroimaging could be attributed to the comorbid epilepsy. While all patients were adults at the time of vEEG, some were younger than 18 at the time of imaging. Age was reported at time of imaging and was calculated at the days between their birthdate and the date of imaging. Comorbidities and confounding factors were obtained from retrospective chart review as well as, after May 2015, direct prospective interview, as described elsewhere [45].

Neuroimaging was obtained as part of the clinical care of these patients. MRI was acquired if prior imaging was not obtained, was more than several years prior to presentation, or of insufficient quality for evaluation of epilepsy. Similarly, X-ray computed tomography (CT) was obtained if the patient had contraindications to MRI and imaging was needed. If MRI or CT scans were collected as part of care in our health system separate from VEEG evaluation, these results were included. Our protocol for PET scanning at the time of vEEG, is to obtain the PET on the morning after admission prior to reduction of antiepileptic medications. Therefore, due to diagnostic uncertainty, PET scans sometimes were obtained in patients who eventually were diagnosed with functional seizures.

Radiologists’ reports of neuroimaging were obtained through chart review. We included neuroimages acquired at the University of California, Los Angeles (UCLA) that were deemed of sufficient quality for a radiologist to review. We excluded neuroimages obtained at outside facilities, irrespective of if they were re-reviewed internally. When multiple images were available, we included the most recent image before or during admission to vEEG and excluded images obtained after VEEG admission. We included all indications for MRI imaging including but not limited to seizure. While the majority of these images were read by fellowship trained neuroradiologists, this was not required. Additionally, we did not include further information obtained by re-review by neurologists, epileptologists, fellowship-trained neuroradiologists, or neuroradiologists specializing in epilepsy unless an addendum was made to the original radiology report.

For the MRIs, images were obtained on a diversity of scanners throughout the health system. We recorded the strength of the magnetic field, model of the scanner, and if a specialized epilepsy-protocol was used. The epilepsy-specific protocol has been developed and used to improve sensitivity for detection of subtle abnormalities like hippocampal sclerosis and focal cortical dysplasia by having 1 mm isotropic volumetric pixels (voxels) and additional sequences perpendicular to the axis of the hippocampus.

The CT images were obtained on a diversity of scanners throughout the health system and had a variety of acquisition protocols. For the PETs, these data were obtained on a single scanner that was maintained throughout the period of the study. The PET scans were acquired on a combined PET-CT scanner but the resolution of the simultaneously acquired CT was limited to only what was necessary for attenuation correction; therefore we did not include interpretations of the CT.
obtained during PET scanning.

The findings and impression from the radiology report were sorted into the following categories: within normal limits (WNL), incidental findings alone, findings unrelated to seizures, nonspecific findings, post-operative imaging, epilepsy risk factors (ERF), borderline epilepsy-associated factors (EAF), and definitive EAF (see Supplemental Table 1 for detailed list of which findings were included in each category). This categorization was based on our interpretation of prior literature and has not been published or validated elsewhere. When analyzing the associations between clinical factors and imaging findings, we excluded post-operative imaging and compared EAF or ERF to all other findings.

For MRI, definitive EAF included but was not limited to hippocampal sclerosis, tuberous sclerosis complex, focal cortical dysplasia, and encophalomalacia [46–56]. Borderline EAF included but was not limited to hippocampal atrophy without T2 hyperintensity, hippocampal T2 hyperintensity without atrophy, subtle or questionable findings for focal cortical dysplasia [57–62]. ERF included cortical based infarcts or T2 hyperintensities, cavernous malformations, old supratentorial intracerebral hemorrhages, and cortically adjacent masses [63–67]. Each of these represent sequelae of risk factors for epilepsy, but they are not associated as strongly with epileptic seizures as the EAF. Nonspecific findings included, but were not limited to, subcortical white matter T2 hyperintensities, meningoiamas without mass effect, and lobar or diffuse cortical volume loss [57,64,68–77]. Findings unrelated to epilepsy included empty sella, Chiari 1 malformation, and T2 hyperintensities consistent with multiple sclerosis [74,78–81]. Incidental findings included, but were not limited to, pineal cysts without mass effect or edema [73,82–84]. All post-operative images were reported separately irrespective of concomitant findings. For CT, these similar definitions were used but hypodensities were seen as compared to T2 hyper-intensities [69,73,85,86].

For PET, definitive EAF included focal hypometabolism in a particular lobe or area of cortex, whereas mild or subtle hypometabolism in a similar region was categorized as a borderline EAF [87–91].

We compared the correspondence between borderline or definitive EAF on MRI and PET using Cohen's kappa statistics. The association between the imaging findings and age, cardiovascular disease, prior antiseizure medications, current antiseizure medications, and delay to diagnosis was evaluated using Student's t-tests, log-normal t-tests for delay to vEEG [92], and Fisher exact tests. Patients with missing data were excluded from the relevant pairwise comparisons (complete case analysis). All intervals reflect 95% confidence intervals of chance, with all frequency-based intervals calculated using binomial exact statistics.

All patients consented for the use of their records in research, and the UCLA Institutional Review Board approved this study. This work is consistent with Declaration of Helsinki. De-identified raw data and code for this study is available at https://SeizureDisorderCenterResearchGroup.org/.

3. Results

The demographics for the patients with neuroimaging are listed in Table 1. During the study period, roughly 1600 unique patients were admitted for vEEG, of which 445 were diagnosed with functional seizures without comorbid epilepsy. MRI from UCLA was available in 58% (256/445) of patients, whereas FDG-PET was available in 20% (87/445), and CT was available in 11% (51/445). There were no systematic differences in age or sex in the availability of imaging at UCLA. Of patients who had an MRI, 32% (82/256) also had an FDG-PET and 19% (49/256) also had a CT. Of patients who had an FDG-PET, 94% (82/87) also had an MRI and 8% (7/87) also had a CT. Overall, 23% (56/256) of MRIs were obtained with epilepsy protocol and 45% (68/150) had a magnet strength of 3 Tesla as compared to 1.5 Tesla. The magnet strength was not specified in the radiologist's report or electronic health record in the remaining 106 MRIs.

The rates of each type of finding on MRI, PET, CT are summarized in

| Table 1 | Demographic table of the age and gender of patients based on what imaging was available. All reflects all patients with functional seizures. Columns reflect patients with each imaging modality available, and rows reflect proportion of patients with the column's imaging modality available that also have the row's imaging modality available. Confidence intervals (CI) are binomial exact. Abbreviations: interquartile range (IQR), magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT). |
| --- | --- | --- | --- | --- |
| Age | Median | IQR | 95% CI | Available Imaging |
| Male | 34 | 32–35 | 33–37 | MRI PET CT |
| Female | 34 | 32–37 | 33–37 | MRI PET CT |
| Female | Prevalence (%) | 95% CI | Available Imaging |
| 75 | 77–79 | MRI PET CT |
| 70–79 | 71–83 | MRI PET CT |
| 68–71 | 66–78 | MRI PET CT |
| Duration | Median (years) | 4 | 3–5 | MRI PET CT |
| Seizure Disorder | IQR | 1–10 | 1.4–11 | 2.5–18 | 1.6–18 |
| Also Available | MRI | Frequency (%) | 51–100 | MRI PET CT |
| 95% CI | 88–99 | MRI PET CT |
| PET | Frequency (%) | 20–32 | 100–14 | MRI PET CT |
| 95% CI | 15–24 | 26–38 | 5–24 |
| CT | Frequency (%) | 11–19 | 8–100 | MRI PET CT |
| 95% CI | 8–15 | 14–24 | 2–14 |

Fig. 1 and listed in Supplemental Table 2. The rates of ERF, borderline EAF, or definitive EAF were 23% (95% CI 18–30%) for MRI, 26% (95% CI 16–35%) for PET, and 2% (95% CI 0–7%) for CT. Cohen's kappa for the association between ERF or EAF on MRI compared to PET was 15% (95% CI -10% to 41%)

Female sex was associated with a decreased rate of ERF or EAF on MRI (odds ratio 0.31, 95% CI 0.16–0.60, Fisher exact p = 0.0005). Patients with ERF or EAF on MRI were taking more ASMs (mean 2.0 versus 1.3 ASMs, 95% CI of difference 0.3–1.1, p = 0.0004) but there was no difference in the number of past ASMs (p = 0.4). Patients with ERF or EAF on MRI also were older (mean 38 versus 32 years, 95% CI of difference 2–11 years, p = 0.003). No other clinical factors were significantly associated with the rate of ERF or EAF on MRI, PET, or CT including age, BMI, number of current ASMs, number of past ASMs, or time from seizure onset to vEEG monitoring (Supplemental Table 3). When specified, there was no association the likelihood of ERF or EAF and if the scan was epilepsy protocol, the magnetic field was 3 Tesla, or the scanner model (Supplemental Table 3).

4. Discussion

While the majority of patients with functional seizures have normal or nonspecific findings on neuroimaging, a substantial minority have findings that have been associated with epilepsy. Therefore, we caution clinicians against anchoring on visually appealing images: epilepsy-associated findings on neuroimaging do not rule out functional seizures. These abnormal findings were associated with more current ASMs, but not past ASMs or delay to vEEG monitoring in our dataset. The interpretation of the observed abnormal findings is an emerging field of research. We discuss two potential hypotheses: cognitive biases of radiologists in a challenging clinical scenario and subtle structural correlates of functional seizures or common comorbidities.

First, we consider contribution of framing bias. This cognitive bias is present when the result of a study is influenced by how the study is presented or how the question is asked [93]. Many neuroimaging findings associated with medication resistant epilepsy are subtle and are appreciated better with specialized imaging protocols [8,20,94,95]. Even though 45% of our MRIs were obtained at 3 T and 23% were obtained with epilepsy protocol, the radiologists were challenged to evaluate uniformly for subtle, clinically relevant findings in a non-ideal setting. Unfortunately, this non-ideal setting is similar to typical clinical practice. All clinicians, radiologists included, need to integrate the
patients with epilepsy roughly matches the frequency of findings in our testing. In contrast, the cost of false negatives from low specificity may diagnostic modalities (e.g. magnetoencephalography, neuropsychiatric video-EEG; and potentially intracranial video-EEG and other neuroimaging findings were clinically correlated with clinical history; scalp (higher sensitivity), but this may come at a cost of decreased specificity of seizure potentially leads to an increased detection of abnormalities findings (17%) compared to ours, these frequencies of EAF and ERF in dataset of patients with epilepsy had an elevated rate of post-surgical incidental findings, 20% had EAF, and 4% had ERF [25]. While this dataset of patients with epilepsy had an elevated rate of post-surgical findings (17%) compared to ours, these frequencies of EAF and ERF in patients with epilepsy roughly matches the frequency of findings in our patients. Therefore, by providing a history of seizures, the non-radiologist raises the pre-test probability that an EAF will be present. This history of seizure potentially leads to an increased detection of abnormalities (higher sensitivity), but this may come at a cost of decreased specificity due to borderline findings being noted as significant. The cost of false positives incurred by this high sensitivity may be low when neuroimaging findings were clinically correlated with clinical history; scalp video-EEG; and potentially intracranial video-EEG and other neurodiagnostic modalities (e.g. magnetoencephalography, neuropsychiatric testing). In contrast, the cost of false negatives from low specificity may be high because the rates of seizure freedom after surgery are higher in lesional (MRI-positive and PET-positive) epilepsy as compared to non-lesional (MRI-negative or PET-negative) epilepsy [97–100]. This bias for high sensitivity may be reflected by the high frequency of borderline EAF. In the PET reports, borderline findings were noted twice as often as clear findings (17% versus 8%). The detection of surgically intervenable lesions is increased by coregistration of PET with MRI [87,88]. However, there was a lack of association between EAF on MRI and PET in our data. This highlights that it was appropriate for radiologists to denote these findings as borderline because, when viewed within the context of a single other neuroimaging modality, the costs of false positives were mitigated.

However, not all of our findings support a framing bias because we did not observe an increased rate of EAF in 3 T or epilepsy-protocol MRIs. The increase in resolution of these modalities may offset the additional framing bias of acquiring specialized imaging. Alternatively, there may be a ceiling effect where patient history was more important than acquisition protocol.

However, this rate of neuroimaging abnormalities in functional seizures cannot be explained entirely by cognitive errors of radiologists. There is increasing quantitative evidence for structural and metabolic abnormalities in patients with functional seizures [38,40]. In specific, the emerging biopsychosocial model of functional neurological disorders includes changes in functional connectivity between areas involved in emotional processing (limbic network), motor control, and volitional or conscious processing of emotions [41]. This limbic network includes the amygdala, hippocampus, and cingulate gyrus that, coincidentally, are the most common localization for medication-resistant epilepsy in adults. In a subset of these patients with higher quality MRI, we quantitatively demonstrated significant atrophy in amygdala and hippocampus in patients with functional seizures as compared to seizure-naive controls and, notably, did not observe a significant difference in the amygdalar volume between functional seizures and temporal lobe epilepsy without hippocampal sclerosis [40]. While the degree of structural findings we see in functional seizures has not been reported in other functional neurological disorders, quantitative left hippocampal volume was inversely correlated with lifetime adverse events in patients with functional movement disorder [101].

Alternatively, these findings may represent structural correlates of common comorbidities of functional seizures. While radiologists qualitatively control for age when interpreting volumes, temporal lobe atrophy increases with age and older patients more frequently had ERF or EAF on MRI [102]. Temporal lobe atrophy also has been reported in depression, PTSD, and survivors of sexual abuse [103–107], all of which are common in patients with functional seizures [108,109]. Migraines also were a common comorbidity of functional seizures; one study demonstrated borderline or definitive mesial temporal sclerosis in 19% (13/73, 95% CI 10–29%) of migraineurs without epilepsy [110]. This markedly elevated rate is different from other studies of incidental hippocampal sclerosis in patients without seizures or migraines [19,20]. One explanation is that the degree of atrophy in functional seizures is less than in patients with temporal lobe epilepsy [40], therefore the findings in functional seizures may be described by radiologists as subtle, mild, or equivocal. Additionally, the increased rate of many EAF

Fig. 1. The rate of each type of neuroimaging finding by imaging modality. Abbreviations: epilepsy risk factor (ERF), epilepsy associated finding (EAF).
and ERF with age may be nonspecific (e.g. post-infarct or post-traumatic encephalomalacia or gliosis, intracranial neoplasms or masses) [111,112].

This understanding of the subtle neuroanatomical changes associated with functional seizures illustrates the importance of nuance and level of evidence for neuroimaging findings. A substantial portion of the reported EAF were borderline and, especially for MRI, many nonspecific findings were reported. Therefore, we suggest that these borderline and nonspecific findings be viewed in the context of other clinical information like history, electrophysiology, and seizure observations. One objective method to integrate history and neurodiagnostic evidence is the clinical diagnostic support tool named Differential Diagnosis of ASMs and had tried 1.5 ASMs in the past, suggesting a delay in referral of framing bias, intra-observer consistency and inter-observer variation, objective method to integrate history and neurodiagnostic evidence is the clinical diagnostic support tool named Differential Diagnosis of Epilepsy versus Functional Seizures (DDESVSFS) [113]. Janocko and colleagues commented that, of the 30% of patients with functional seizures who had abnormal imaging, the majority of findings were nonspecific. In comparison, 50% of patients with epilepsy had abnormal imaging. In other studies, 60% of patients with functional seizures with comorbid epilepsy had abnormal imaging [10,43]. However, they and others who made similar observations did not quantify the level of certainty or frequency of neuroimaging findings more strongly associated with epilepsy. Therefore, some degree of structural abnormalities may reflect the underlying neural network changes seen in functional seizures, but the heterogeneity of findings and the level of prior evidence make this explanation a conjecture. Further direct and controlled comparisons between imaging and clinical findings in epilepsy, functional seizures, other functional neurological disorders, and appropriate psychiatric and medical comorbidities are necessary to characterize the unique imaging correlates of disease.

A direct comparison to patients with epilepsy would need to include temporal lobe epilepsy with and without hippocampal sclerosis, as well as non-temporal lobe epilepsies. Additionally, to evaluate the influence of framing bias, intra-observer consistency and inter-observer variation, each neuroimage would need to be re-adjudicated by multiple radiologists in a research context. These comparisons across patient groups would be most valuable if imaging results were viewed in the context of clinical history (e.g. DDESVSFS [114] and Functional Seizures Likelihood Score [45]) and EEG [114], which would require more discussion. While we did not compare directly the rate of neuroimaging findings in functional seizures to a similar population of patients with epilepsy at our center or re-adjudicate the radiologists’ impression, the current work provides further details regarding the types of neuroimaging findings observed in patients with functional seizures in clinical practice.

We hypothesized that abnormal neuroimaging may delay referral to vEEG monitoring or prompt more trials of ASMs. The increased rate of ASM treatment and polytherapy in patients with ERF or EAF supported this hypothesis, but this did not translate to a difference in diagnostic delay. This supports that abnormal MRI likely influenced clinical management by increasing clinician’s suspicion for epilepsy. The International League Against Epilepsy recommends referral for vEEG monitoring when patients with seizures are not seizure free after two appropriately chosen and tolerated ASMs. However, the average patient with functional seizures and ERF or EAF on MRI was currently taking 2 ASMs and had tried 1.5 ASMs in the past, suggesting a delay in referral [5,92]. This type of hesitancy for referral also is seen in patients with functional seizures to a similar population of patients with epilepsy at our center or re-adjudicate the radiologists’ impression, the current work provides further details regarding the types of neuroimaging findings observed in patients with functional seizures in clinical practice.

We hypothesized that abnormal neuroimaging may delay referral to vEEG monitoring or prompt more trials of ASMs. The increased rate of ASM treatment and polytherapy in patients with ERF or EAF supported this hypothesis, but this did not translate to a difference in diagnostic delay. This supports that abnormal MRI likely influenced clinical management by increasing clinician’s suspicion for epilepsy. The International League Against Epilepsy recommends referral for vEEG monitoring when patients with seizures are not seizure free after two appropriately chosen and tolerated ASMs. However, the average patient with functional seizures and ERF or EAF on MRI was currently taking 2 ASMs and had tried 1.5 ASMs in the past, suggesting a delay in referral [5,92]. This type of hesitancy for referral also is seen in patients with ERF or EAF. This delay could be due to a ceiling effect because the average delay to vEEG monitoring was 9–10 years in our patients both with and without abnormal MRI. The curious increase in the rate of abnormal MRI in men also was observed in a recent Indian dataset, but the interpretation remains unclear [11].

An alternative explanation for the increased rate of ERF or EAF in patients taking ASMs is that the ASMs could have an effect on neuroimaging findings. While the cerebellar effect of sodium channel blockers is established, we did not frequently observe cerebellar atrophy in patients with functional seizures. Outside the cerebellum, most studies of the effect of ASMs on neuroimaging focus on differences observed on functional MRI [116]. One study demonstrated decreased amygdalar volume in adolescents with bipolar disorder and a 6-week exposure to valproate [117]. However, other MRI studies of patients with bipolar disorder on long term valproate did not observe similar differences [118,119]. Therefore, while we could not definitively determine that increased ASM use was a cause or an effect of ERF or EAF in this cross-sectional study, prior literature suggests that these neuroimaging findings would be unlikely to be caused by ASMs alone.

An important limitation in our approach is that neuroimages were obtained as part of clinical care and as such were not available for all patients and were not acquired on the same scanners with the same protocols. While we expect the quality of neuroimaging at our comprehensive epilepsy center to be higher than a non-specialized center, this limited data quality matches what is often available clinically. Additionally, when compared to the aforementioned studies of MRI findings in patients without seizures [15,18–24], a higher proportion of our images were obtained on 3 Tesla scanners, and many were obtained with the specialized epilepsy-protocol. While we did not observe increased rates of EAF or ERF with these higher quality images in patients with functional seizures, our elevated rate of incidental and nonspecific findings may be attributed to these differences in quality. Future studies that directly compare patients with functional seizures to seizure-naïve controls and patients with epilepsy would improve the interpretation of neuroimaging findings in patients with functional seizures.

Additionally, our rate of image availability was low and matched prior similar studies [7,120,121]. While we did not observe associations between confounding factors and imaging availability, there likely was a bias to obtain neuroimaging in patients with a higher pretest probability of epilepsy or who had demonstrated abnormalities on outside imaging. Therefore, these numbers may represent an overestimate of the rate of neuroimaging findings in patients with functional seizures. Additionally, while our center has pediatric vEEG monitoring, we excluded this population from this work, so our results may not generalize to pediatric or adolescent patients with functional seizures.

5. Conclusions

Neuroimaging findings associated with epilepsy do not rule out functional seizures. While the majority of patients had normal neuroimaging, a substantial proportion had findings that are strongly associated with epilepsy [48]. These findings likely represent a framing bias of radiologists evaluating neuroimaging of patients with a history of seizures or represent subtle structural or metabolic correlates of the underlying network alterations in functional seizures. In the future, these imaging correlates of disease can be clarified by direct comparisons between patients with functional seizures, epilepsy, other functional neurological disorders, and psychiatric disorders.

Conflicts & ethical publication

Drs. Engel, Stern, Lee, Hickman, Connerney, Silverman, Beimer, Stacey, Salamon, and Kerr have clinical responsibilities that include the diagnosis and treatment of patients with epilepsy and non-epileptic seizures. The remaining authors have no declared conflicts of interest. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Acknowledgements

The authors thank Kirk Shattuck and Marc Nuwer for organization support, access to the data, and technical support. This work was supported by the National Institutes of Health (R25 NS065723, T32 GM08042, T90 DA022768, R90 DA022768, R90 DA023422, T32 GM008185, R01 NS033310, & P20 NS080181) and the William M. Keck...
adolescents and adults with bipolar disorder, Arch. Gen. Psychiatry 60 (2003) 1201–1208.

[105] V. Dhikav, K.S. Anand, Is hippocampal atrophy a future drug target? Med. Hypotheses 68 (2007) 1300–1306.

[106] L.L. Altshuler, O.A. Abulseoud, L. Falond-Ross, G. Bartozkis, S. Chang, J. Mintz, G. Hellemaan, H.V. Vinters, Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder, Bipolar Disord. 12 (2010) 541–549.

[107] J.E. Hardee, J.C. Thompson, A. Puce, The left amygdala knows fear: laterality in the amygdala response to fearful eyes, Soc. Cogn. Affect. Neurosci. 3 (2008) 47–54.

[108] W.T. Kerr, E.A. Janio, C.T. Braesch, J.M. Le, J.M. Hori, A.B. Patel, N.L. Gallardo, J. Baurjian, S.R. D’Amбросio, A.M. Chau, E.S. Hwang, E.C. Davis, A. Buchard, D. Torres-Barba, M. Al Banna, S.E. Barratt, A.Y. Cho, J. Engel Jr., M.S. Cohen, J. M. Stern, Identifying psychogenic seizures through comorbidities and medication history, Epilepsia 58 (2017) 1852–1860.

[109] W.T. Kerr, E.A. Janio, C.T. Braesch, J.M. Le, J.M. Hori, A.B. Patel, N.L. Gallardo, J. Baurjian, A.M. Chau, E.S. Hwang, E.C. Davis, A. Buchard, D. Torres-Barba, S. D’Amбросio, M. Al Banna, A.Y. Cho, J. Engel Jr., M.S. Cohen, J.M. Stern, An objective score to identify psychogenic seizures based on age of onset and history, Epilepsy Behav. 80 (2018) 75–82.

[110] M.H. Bagherti, R. Jalli, A. Hoseyni Moghadam, New MRI finding in migraineurs: mesial temporal sclerosis, J. Biomed. Phys. Eng. 10 (2020) 459–466.

[111] C. Arnold Fiebelkorn, P. Vemuri, A.A. Rabinstein, M.M. Miedke, S.A. Przybelski, K. Kantarcı, D.T. Jones, R.D. Brown Jr., D.S. Knopman, R.C. Petersen, C. R. Jack Jr., J. Graff-Radford, Frequency of acute and subacute infarcts in a population-based study, Mayo Clin. Proc. 93 (2018) 300–306.

[112] J.L. Fisher, J.A. Schwartzbaum, M. Wernsch, J.L. Wiemels, Epidemiology of brain tumors, Neurol. Clin. 25 (2007) 867–890 (vii).

[113] N.J. Janocko, J. Jing, Z. Fan, D.L. Tesgarden, H.K. Villarreal, M.L. Morton, O. Groover, D.W. Loring, D.L. Drane, M.B. Westover, I. Karakus, DDESVFSS: a simple, rapid and comprehensive screening tool for the differential diagnosis of epileptic seizures VS functional seizures, Epilepsy Res. 171 (2021) 106563.